Phase 3 N=41 Ketamine Infusion for Comorbid PTSD and Chronic Pain
PTSD · Chronic Pain
Primary: Impact of Event Scale-Revised (IES-R) — 36.33333333; 37; 10.44444444; 15.64705882 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,462 Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)
Hypercholesterolemia · Atherosclerotic Cardiovascular Disease
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 385; 758; 1143; 97 Participants
Phase 3 N=11,016 THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death
Acute Ischaemic Stroke · Transient Ischaemic Attack
Primary: Composite of Subsequent Stroke or Death — 303; 362 Participants — p=0.015
Phase 3 N=31 Supplementation of Glutamine and Fish Oil Versus Placebo in Patients With Heart Failure
Heart Failure
Primary: Baseline Skeletal Muscle Function Capacity- Isometric Contractions (PKTQ/BW) — 177; 196; 76; 90 Percent
Phase 3 N=95 Effect of Kuvan on Neurocognitive Function, Blood Phenylalanine Level, Safety, and Pharmacokinetics in Children With PKU
Phenylketonuria
Primary: Full-Scale Intelligence Quotient (FSIQ) Score — 101.06; 103.64; 104.69; 103.78 score on a scale
Phase 3 N=166 Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy
Primary: Baseline for the North Star Ambulatory Assessment (NSAA) Total Score — 23.1; 24.5; 22.7 score on a scale
Phase 3 N=84 Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease
Fabry Disease
Primary: Number Of Participants Experiencing Adverse Events (AEs) — 80; 26; 1; 0 Participants
Phase 3 N=80 Propofol in Obese Children
Pharmacodynamics · Obesity
Primary: Dose of Propofol That Caused Loss of Consciousness in 95% (ED95) of Obese and Non-obese Children — 2; 2.125 mg/kg
Phase 3 N=450 Study of BBIL's ROTAVAC® and ROTAVAC 5CM Vaccines in Zambia
Diarrhea · Diarrhea Rotavirus
Primary: Geometric Mean Concentration Using WC3 as the Viral Lysate — 18.1; 14.0 U/ml
Phase 3 N=371 Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission
Rheumatoid Arthritis
Primary: Percentage of Participants With Simplified Disease Activity Index (SDAI) Remission (≤ 3.3) at Week 48: Etanercept Monotherapy vs. Methotrexate Monotherapy — 28.7; 49.5…
Phase 3 N=407 Effect of Mepolizumab in Severe Bilateral Nasal Polyps
Nasal Polyps
Primary: Change From Baseline in Total Endoscopic Nasal Polyps Score at Week 52 — 0.0; -1.0 Scores on a scale — p=<0.001
Phase 3 N=65 8-Week Atopic Dermatitis (AD) Treatment Study
Atopic Dermatitis Eczema
Primary: Severity Scoring of Atopic Dermatitis (SCORAD) Amongst Subjects With Moderate Atopic Dermatitis — -12.2; 9.3; -17.5 units on a scale — p=<0.05
Phase 3 N=594 Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis
Anemia in Chronic Kidney Disease in Non-dialysis Patients
Primary: Percentage of Participants With a Hemoglobin (Hb) Response to Treatment at Two Consecutive Visits During the First 24 Weeks of Treatment Without Rescue Therapy Prior to…
Phase 3 N=751 A Study (Study 1) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea
Facial Papulopustular Rosacea
Primary: The Absolute Change From Day 0/Baseline in the Inflammatory Lesion Count at Week 12 — 17.56; 15.34 Lesions — p=0.0031
Phase 3 N=153 DEF-314 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY
Cardiac Disease
Primary: Absolute Value of LVEF Percentage Differences From CMR by Blinded Reader — 6.10; 6.38; 4.93; 6.18 Percent Ejection Fraction — p=0.868